SFU
ACOR

Stonehage Fleming (UK)’s Acorda Therapeutics ACOR Stock Holding History

Stonehage Fleming (UK)’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-3
Closed -$12K – 343
2014
Q3 		$12K Buy
+3
New +$11.3K 0.01% 294

Other funds holding ACOR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

Stonehage Fleming (UK)'s ACOR Position: Q4 2014 in Review

Stonehage Fleming (UK) sold out of Acorda Therapeutics (ACOR) in Q4 2014, closing a stake of 3 shares — an estimated $12K sold.

Stonehage Fleming (UK) first reported a position in ACOR in Q3 2014 and held it in 1 quarter. The position peaked at $12K in Q3 2014. 179 funds tracked by Wall St. Rank hold ACOR as of Q4 2014.

  • Stonehage Fleming (UK) reported no remaining Acorda Therapeutics position as of Q4 2014 after selling out during the quarter.
  • Stonehage Fleming (UK) sold 3 Acorda Therapeutics shares in Q4 2014, an estimated $12K.
  • Stonehage Fleming (UK) first reported a position in Acorda Therapeutics in Q3 2014 and held it in 1 quarter.
  • Stonehage Fleming (UK)'s Acorda Therapeutics position peaked at $12K in Q3 2014.
  • 179 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q4 2014.

Based on Stonehage Fleming (UK)'s 13F filing for Q4 2014, filed 11 Oct 2019.